An Open-Label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX P/N Compared with Plasma for Rapid Reversal of Coagulopathy

Grants and Contracts Details

StatusFinished
Effective start/end date1/7/10 → 9/30/13

Funding

  • CSL Behring GmbH: $37,184.00